logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Bruce Anthony Dressman

USPTO Granted Patents = 32


 

Average Co-Inventor Count = 10.0

ph-index = 7

Forward Citations = 205(Granted Patents)


Company Filing History:

goldMedal11 out of 4,447 
 
Eli Lilly and Company
 patents
silverMedal9 out of 174 
 
Agouron Pharmaceuticals, Inc.
 patents
bronzeMedal2 out of 35 
 
Athena Neurosciences, Inc.
 patents
4. 1 out of 202 
 
Elan Pharmaceuticals, Inc.
 patents
5. 12 out of 832,880 
Other
 patents
where one patent can have more than one assignee

Years Active: 1996-2015

Loading Chart...
Loading Chart...
Loading Chart...
32 patents (USPTO):Explore Patents
1. 9056844 - 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists (2015-06-16),
2. 7915424 - Pyridyl derivatives and their use as mGlu5 antagonists (2011-03-29),
3. 7868014 - 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists (2011-01-11),
4. 7390801 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2008-06-24),
5. 6951854 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2005-10-04),
6. 6906056 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2005-06-14),
7. 6696438 - Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2004-02-24),
8. 6693199 - Method of making HIV protease inhibitors (2004-02-17),
9. 6683075 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use (2004-01-27),
10. 6667305 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-12-23),
11. 6653303 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-11-25),
12. 6635632 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-10-21),
13. 6632811 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-10-14),
14. 6610680 - Non-peptidyl vasopressin V1A antagonists (2003-08-26),
15. 6579867 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-06-17),

Title: Bruce Anthony Dressman: Innovator in Pharmaceutical Chemistry

Introduction

Bruce Anthony Dressman is a prolific inventor based in Indianapolis, IN. With an impressive portfolio comprising 32 patents, he has made significant contributions to pharmaceutical chemistry, particularly in the development of compounds targeting specific receptors in the human body.

Latest Patents

Among his most recent inventions are two noteworthy patents focusing on receptor antagonists. The first patent details 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists. This invention describes a mGlu2/3 receptor antagonist along with its uses and methods for preparation. The second patent involves pyridyl derivatives directed toward mGlu5 antagonists, which are significant for treating or preventing various disorders related to the mGlu5 receptor. This includes a complex formula showcasing the versatility of the compounds for medicinal applications.

Career Highlights

Bruce Dressman's career has seen him affiliated with prominent firms, including Eli Lilly and Company. His work in pharmaceutical research has led to numerous innovative drugs and therapeutic methods that aim to improve human health through targeted receptor interaction.

Collaborations

During his journey, Dressman has collaborated with notable professionals in the field, including Stephen W. Kaldor and Thomas Charles Britton. These collaborations have fostered a rich environment for innovation and advancement in pharmaceutical research.

Conclusion

Bruce Anthony Dressman stands out as an influential figure in the realm of pharmaceutical innovation. His extensive patent portfolio and collaborative efforts highlight his dedication to advancing medical science and improving therapeutic options for patients. Through his work, he exemplifies the essence of innovation in modern pharmaceutical chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…